文献速递肝病

胆汁淤积性肝病的肝移植:时机与疾病复发

Liver transplantation for cholestatic liver diseases: Timing and disease recurrence.
PubMed 文献 · Hepatology · 2025-02-17

本文综述了原发性胆汁性胆管炎(PBC)和原发性胆管炎(PSC)患者肝移植的全程管理,指出MELD评分不能充分反映疾病特异性并发症,等待名单期间风险高且漫长,移植后结局总体良好但5-10年复发率为15%-35%,PBC复发可用熊去氧胆酸,PSC复发尚无有效药物,控制IBD活动是关键可调控因素。

要点

  • PBC和PSC占北美和欧洲肝移植的8%-14%,移植后5-10年疾病复发率为15%-35%。
  • MELD评分不能充分反映PBC/PSC的疾病特异性并发症,如复发性胆管炎、恶性肿瘤风险、严重门脉高压和肌少症。
  • PBC移植后使用熊去氧胆酸明确有益,PSC复发尚无有效药物治疗,控制IBD活动是潜在可调控风险因素。

核心结论

  • PBC和PSC患者肝移植需从等待名单到移植后管理的个体化全程策略,以优化结局和长期生存。

研究设计与样本

  • 综述,总结PBC和PSC患者从移植列表到移植后管理的全程。

主要发现

  • PBC和PSC占北美和欧洲肝移植的8%-14%。
  • MELD评分及其衍生指标不能充分反映PBC/PSC相关并发症,如复发性胆管炎、恶性肿瘤风险、严重门脉高压和肌少症。
  • 移植后结局总体良好,但移植后5-10年疾病复发率为15%-35%,且随时间推移复发率增加。
  • PBC移植后使用熊去氧胆酸明确有益,PSC复发目前无有效药物治疗。

关键数值与推荐

  • 移植后5-10年疾病复发率为15%-35%。
  • PBC和PSC占北美和欧洲肝移植的8%-14%。

临床怎么用

  • PBC移植后使用熊去氧胆酸明确有益。
  • PSC复发目前无有效药物治疗。
  • 作者认为加强控制IBD活动至关重要,是rPSC潜在重要可调控风险因素,包括必要时升级药物治疗和适时结肠切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Though rare, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) account for 8%-14% of liver transplants (LTs) in North America and Europe and the journey of these patients across the peri-transplant period is unique. Equitable access to LT is an important challenge, as the MELD score and its derivatives inadequately reflect the morbidity and mortality related to these diseases failing to capture disease-specific complications, such as recurrent cholangitis, malignancy risk, severe portal hypertension, and sarcopenia. The waitlist experience is high-risk, prolonged, and a distinct form of "MELD purgatory." Once barriers to access are overcome, posttransplant outcomes are generally excellent; however, disease recurrence affects 15%-35% at 5-10 years after LT with increasing rates over time. Diagnosing recurrence is challenged by a broad differential for posttransplant biliary injury, and the risk factors for its development remain controversial. While post-LT use of ursodeoxycholic acid in PBC is clearly beneficial, no effective medical therapy currently exists for recurrent PSC. A heightened focus on control of inflammatory bowel disease activity is critical as a potentially important modifiable risk factor for rPSC, including escalation of medical therapy as needed and timely colectomy when indicated. This review outlines the journey for patients with PBC and PSC, from transplant listing to posttransplant management, emphasizing the need for unique and tailored approaches to optimize outcomes and long-term survival.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cançado GGL, Deeb M, Gulamhusein AF, et al. Liver transplantation for cholestatic liver diseases: Timing and disease recurrence. Hepatology. 2025. PMID: 39960305. doi:10.1097/HEP.0000000000001268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。